Forsters advises on the £50.5 million sale of Bova Holdings Limited to listed Vimian Group
A Forsters team led by Corporate Partner, Naomi Trinh, together with Senior Associate, Daniel Bryan, Counsel, Joe Beeston, and Trainee Solicitor, Molly Haynes, advised Nick Bova, the founder and CEO of Bova Holdings Limited (“Bova”), to Vimian Group’s speciality pharma segment, Nextmune Holding BV (“Nextmune”), for £50.5 million plus a potential further £25.5 million over the next three years.
Bova is the UK’s leading companion animal health specialty pharmaceuticals company, serving UK animal hospitals and veterinary clinics and with a European online market, while Vimian Group is listed on Nasdaq First North Growth Market.
The deal reflects the significant growth of the customised specialty pharmaceuticals area within the animal health market.
“We are pleased to join Nextmune and Vimian Group’s home for entrepreneurs. We are dedicated to improving animal welfare by developing novel and innovative specialty pharmaceuticals in close collaboration with veterinarians. Through this partnership we can realise our vision to become the leading companion animal health specialty pharmaceuticals company globally”, says Nick Bova, who will continue to head Bova.